The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics
Open accessAbstract
As clinical applications for chimeric antigen receptor T cell (CART) therapy extend beyond early phase trials, commercial manufacture incorporating cryopreservation steps becomes a logistical necessity. The effect of cryopreservation on CART characteristics is unclear. We retrospectively evaluated the effect of cryopreservation on product release criteria and in vivo characteristics in 158 autologous CART products from 6 single-center clinical trials. Further, from 3 healthy donor manufacturing runs, we prospectively identified differentially expressed cell surface markers and gene signatures among fresh versus cryopreserved CARTs. Within 2 days of culture initiation, cell viability of the starting fraction (peripheral blood mononuclear cells [PBMNCs]) decreased significantly in the cryo-thawed arm compared to the fresh arm. Despite this, PBMNC cryopreservation did not affect final CART fold expansion, transduction efficiency, CD3%, or CD4:CD8 ratios. In vivo CART persistence and clinical responses did not differ among fresh and cryopreserved final products. In healthy donors, compared to fresh CARTs, early apoptotic cell-surface markers were significantly elevated in cryo-thawed CARTs. Cryo-thawed CARTs also demonstrated significantly elevated expression of mitochondrial dysfunction, apoptosis signaling, and cell cycle damage pathways. Cryopreservation during CART manufacture is a viable strategy, based on standard product release parameters. The clinical impact of cryopreservation-related subtle micro-cellular damage needs further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“POC manufacturing enables the delivery of fresh CAR-T cells, which were shown earlier to have higher in vitro antitumor activity and lesser microcellular damage than the frozen,4,5”
From Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, Panch et al. showed recovery and viability of PBMCs was significantly reduced after freezing and thawing compared to fresh apheresis products (39). Nevertheless, the recovery of mononuclear cells after thawing was sufficient for consistent manufacturing of CAR T cells, without evidence of significant differences in expansion, transduction efficiency or overall subset composition (39)”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Self-citationClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,363
Self-citationAli, S. A., Shi, V., Marić, I., Wang, M. L., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler‐Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 776
Self-citationRuella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0201-9 · Cited by 659
Self-citationClinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Brudno, J. N., Somerville, R. P. T., Shi, V. J., Rose, J. J., Halverson, D. C., Fowler, D. H., Gea‐Banacloche, J., Pavletic, S. Z., Hickstein, D. D., Lu, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5929 · Cited by 605
Self-citationA guide to manufacturing CAR T cell therapies
Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.025 · Cited by 403
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–107 of 107
Biological and Clinical Applications of Dimethyl Sulfoxide: Evidence and Safety Considerations
Huang, Z., & Wang, J. (2026) · Biomolecules · doi:10.3390/biom16101534
Impact of cryopreservation on PBMC-derived CAR-T cell manufacturing outcomes: a systematic review
Al-Wreidat, R. A., Alshwayyat, S., Maharma, L. A., & Al-Hussaini, M. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1876909
Cryopreservation of cell-based therapies with enhanced cell viability and therapeutic efficacy
Lee, A. H., Tran, K. T. M., Hostetler, A., Lei, K., Tian, J., Mursalova, S., Lau, A., Liu, G. W., Gorelick, C., Irvine, D. J., et al. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.07.019
Domingo-Lopez, D., Tarpey, R., Brennan, B., Boyle, B. D., Alsharabasy, A. M., Mallick, A., Bellavia, G., Pandit, A., Duffy, G. P., & Levey, R. (2026) · Advanced Functional Materials · doi:10.1002/adfm.78103
Fast and Ultra-Fast mRNA-Engineered Anti-CA125/MUC16 CAR-T-Cells: An In Vitro Study
Гуламовна, А. К., Pilunov, A., Maleeva, A., Михайловна, К. Т., & Bozhenko, V. (2026) · Biomedicines · doi:10.3390/biomedicines14102147
Immunophenotyping of Cellular Therapy Products Against Oncogenic and Viral Targets
Lazarski, C. A., Datar, A. A., Hanley, P. J., & Srivastava, S. K. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5607-5_13
Self-citationWu, Q., Jiang, M., Li, Y., Huo, H., Cheng, H., Jia, T., Wang, Y., Wang, Z., Ji, M., Lin, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1981337
Metadata
- Authors
- Panch, S. R., Srivastava, S. K., Elavia, N., McManus, A., Liu, S., Jin, P., Highfill, S. L., Li, X., Dagur, P., Kochenderfer, J. N., Fry, T. J., Mackall, C. L., Lee, D., Shah, N. N., & Stroncek, D. F.
- Affiliations
- National Institutes of Health (US)
- National Heart, Lung, and Blood Institute (US)
- Stanford University (US)
- University of Virginia (US)
- Corresponding author
- Panch, Sandhya R.
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 27
- Issue
- 7
- Pages
- 1275-1285
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC6612799
- OpenAlex
- W2947301297
- Cited by
- 107
- References
- 42
- Citations by year
- 2026: 17 · 2025: 12 · 2024: 16 · 2023: 18 · 2022: 22 · 2021: 12 · 2020: 7 · 2019: 3
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Center for Outcomes Research and Evaluation, Yale School of Medicine
- NIH Clinical Center
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- chimeric antigen receptor T cells, cryopreservation, autologous CAR T-cell therapy, CAR T cell manufacturing, cell viability, apoptosis, mitochondrial dysfunction, cell surface markers, gene expression signatures, CAR T cell persistence
- MeSH terms
- Receptors, Chimeric Antigen, Adolescent, Adult, Aged, Autoantigens, Cell Cycle, Cell Survival, Child, Female, Humans, Male, Middle Aged, Neoplasms, Phenotype, Prospective Studies, Retrospective Studies, T-Lymphocytes, Cryopreservation, Immunotherapy, Adoptive, CD4-CD8 Ratio, Apoptosis, Young Adult, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
